Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Supernus Pharmaceuticals revenue
Supernus Pharmaceuticals's revenue is $661.8 million.
What is Supernus Pharmaceuticals's revenue?
- Supernus Pharmaceuticals's revenue growth from 2011 to 2024 is 82,318.06%.
- Supernus Pharmaceuticals has 448 employees, and the revenue per employee ratio is $1,477,270.
- Supernus Pharmaceuticals's peak quarterly revenue was $177.4M in 2022(q3).
- Supernus Pharmaceuticals peak revenue was $667.2M in 2022.
- Supernus Pharmaceuticals annual revenue for 2023 was 607.5M, -8.95% growth from 2022.
- Supernus Pharmaceuticals annual revenue for 2024 was 661.8M, 8.94% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Supernus Pharmaceuticals historical revenue
Supernus Pharmaceuticals's peak revenue was $667.2M in 2022. The peak quarterly revenue was $177.4M in 2022(q3).
Supernus Pharmaceuticals's revenue increased from $803.0k in 2011 to $661.8M currently. That's a 82,318.06% change in annual revenue.
Supernus Pharmaceuticals annual revenue
Supernus Pharmaceuticals annual revenue over time
| Fiscal year / year | Supernus Pharmaceuticals revenue |
|---|---|
| 2011 | $803,000 |
| 2012 | $1.5M |
| 2013 | $12.0M |
| 2014 | $92.7M |
| 2015 | $147.5M |
| 2016 | $215.0M |
| 2017 | $302.2M |
| 2018 | $408.9M |
| 2019 | $392.8M |
| 2020 | $520.4M |
| 2021 | $579.8M |
| 2022 | $667.2M |
| 2023 | $607.5M |
| 2024 | $661.8M |
Rate Supernus Pharmaceuticals' financial transparency
Supernus Pharmaceuticals annual growth
Supernus Pharmaceuticals saw the greatest revenue growth in 2013, when revenue increased by 712.09%.
Supernus Pharmaceuticals had the lowest revenue growth in 2019, when revenue changed by -3.95%.
Supernus Pharmaceuticals annual growth rate over time
| Year | Supernus Pharmaceuticals growth |
|---|---|
| 2012 | 84%↑ |
| 2013 | 712%↑ |
| 2014 | 671%↑ |
| 2015 | 59%↑ |
| 2016 | 46%↑ |
| 2017 | 41%↑ |
| 2018 | 35%↑ |
| 2019 | -4%↓ |
| 2020 | 32%↑ |
| 2021 | 11%↑ |
| 2022 | 15%↑ |
| 2023 | -9%↓ |
| 2024 | 9%↑ |
Supernus Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Supernus Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2011 | - | - | - | $42,000 |
| 2012 | $208,000 | $91,000 | $91,000 | $1.1M |
| 2013 | $147,000 | $281,000 | $1.3M | $10.3M |
| 2014 | $9.1M | $29.7M | $22.7M | $31.2M |
| 2015 | $28.7M | $35.7M | $39.4M | $43.7M |
| 2016 | $44.2M | $51.6M | $56.8M | $62.4M |
| 2017 | $57.6M | $75.8M | $80.4M | $88.4M |
| 2018 | $90.4M | $99.5M | $103.0M | $115.9M |
| 2019 | $85.5M | $104.7M | $102.1M | $100.4M |
| 2020 | $95.0M | $126.7M | $155.1M | $143.6M |
| 2021 | $130.9M | $141.3M | $148.5M | $159.1M |
| 2022 | $152.5M | $170.1M | $177.4M | $167.3M |
| 2023 | $153.8M | $135.6M | $153.9M | $164.3M |
| 2024 | $143.6M | $168.3M | $175.7M | $174.2M |
Supernus Pharmaceuticals jobs nearby
Do you work at Supernus Pharmaceuticals?
Did Supernus Pharmaceuticals meet its revenue projections?
Supernus Pharmaceuticals financial information
| CEO | Jack A. Khattar |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 448 |
| Date Founded | 2005 |
| Headquarters | Rockville, Maryland |
| Number of Locations | 1 |
| Revenue | $661.8M |
| Net Income | $60,711,000 |
| Gross Proft | $583.9M (2024) |
| EBITDA | $87.6M (2023) |
| PE Ratio | 26.69 |
| Tax Rate | 0.2% |
| Market Capitalization | $2.0B |
| Total Assets | $1,702,508,000 |
| Ticker | SUPN |
Supernus Pharmaceuticals jobs you might like
Supernus Pharmaceuticals financing
Supernus Pharmaceuticals received early financing of $27.5M on 2006-01-12.
| Series | Round size | Date |
|---|---|---|
| Series A | $27.5M | 01/2006 |
| Debt Financing | $30M | 01/2011 |
| Private Equity | $42M | 01/2012 |
| Post Ipo Debt | $90M | 04/2013 |
| Post Ipo Debt | $350M | 03/2018 |
Supernus Pharmaceuticals investors
| Investors | Security type |
|---|---|
| New Enterprise Associates (NEA) | Series A |
| OrbiMed Advisors | Series A |
Supernus Pharmaceuticals competitors
Supernus Pharmaceuticals's top competitor, Jazz Pharmaceuticals, earned an annual revenue of $4.1B.
Supernus Pharmaceuticals's smallest competitor is VistaGen Therapeutics with revenue of $1.1M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| DURECT | $76,438 | $2.0M | 88 | - |
| Jazz Pharmaceuticals | $101,973 | $4.1B | 1,210 | 51 |
| Santarus | $70,584 | $218.0M | 290 | - |
| Tonix Pharmaceuticals | $66,193 | $12.7M | 26 | 16 |
| KemPharm | $68,560 | $23.6M | 22 | - |
| Zogenix | $71,837 | $81.7M | 90 | - |
| Avanir Pharmaceuticals | $65,825 | $115.0M | 200 | - |
| VistaGen Therapeutics | $45,067 | $1.1M | 18 | - |
| Axsome Therapeutics | $51,260 | $385.7M | 29 | 349 |
| Salix Pharmaceuticals | $106,558 | $1.1B | 1,000 | - |
Supernus Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Supernus Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Supernus Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Supernus Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Supernus Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Supernus Pharmaceuticals. The data presented on this page does not represent the view of Supernus Pharmaceuticals and its employees or that of Zippia.
Supernus Pharmaceuticals may also be known as or be related to SUPERNUS PHARMACEUTICALS INC, SUPERNUS PHARMACEUTICALS INC., Supernus Pharmaceuticals, Supernus Pharmaceuticals Inc and Supernus Pharmaceuticals, Inc.